{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T20:15:49Z","timestamp":1769199349270,"version":"3.49.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.pbb.2017.05.010","type":"journal-article","created":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T06:00:39Z","timestamp":1496383239000},"page":"22-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Preclinical abuse liability assessment of ABT-126, an agonist at the \u03b17 nicotinic acetylcholine receptor (nAChR)"],"prefix":"10.1016","volume":"158","author":[{"given":"Thomas J.","family":"Hudzik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana M.","family":"Basso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"James J.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William M.","family":"Bracken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric G.","family":"Mohler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy L.","family":"Kohlhaas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Haig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Gault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2017.05.010_bb0010","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.neuropharm.2013.04.034","article-title":"Cognitive function during nicotine withdrawal: implications for nicotine dependence treatment","volume":"76","author":"Ashare","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2017.05.010_bb0020","article-title":"The neuronal pathways mediating the behavioral and addictive properties of nicotine, in Nicotine Psychopharmacology pp 209\u2013233","author":"Balfour","year":"2009","journal-title":"Spring"},{"key":"10.1016\/j.pbb.2017.05.010_bb0025","doi-asserted-by":"crossref","first-page":"P817","DOI":"10.1016\/j.jalz.2013.05.1755","article-title":"Preclinical characterization of a selective alpha-7 neuronal nicotinic acetylcholine receptor agonist ABT-126: a novel therapeutic agent for the treatment of cognitive impairment in Alzheimer's disease and schizophrenia","volume":"4","author":"Bitner","year":"2013","journal-title":"Alzheimer's & Dementia: The Journal of the Alzheimer's Association"},{"key":"10.1016\/j.pbb.2017.05.010_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(03)01558-9","article-title":"Vocalizations during withdrawal from opiates and cocaine: possible expressions of affective distress","volume":"467","author":"Covington Iii","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2017.05.010_bb0035","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s002130051079","article-title":"Acute and chronic effects of nornicotine on locomotor activity in rats: altered response to nicotine","volume":"145","author":"Dwoskin","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2017.05.010_bb0040","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.neuroscience.2006.12.036","article-title":"Neuroprotection afforded by nicotine against oxygen and glucose deprivation in hippocampal slices is lost in \u03b17 nicotinic receptor knockout mice","volume":"145","author":"Egea","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.pbb.2017.05.010_bb0045","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pbb.2003.09.016","article-title":"Effects of nicotine on elevated plus maze and locomotor activity in male and female adolescent and adult rats","volume":"77","author":"Elliott","year":"2004","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2017.05.010_bb0050","author":"FDA","year":"2017","journal-title":"Guidance for Industry: Assessment of Abuse Potential of Drugs."},{"issue":"2","key":"10.1016\/j.pbb.2017.05.010_bb0055","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.115.226803","article-title":"Effects of nicotinic acetylcholine receptor agonists in assays of acute pain-stimulated and pain-depressed behaviors in rats","volume":"355","author":"Freitas","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2017.05.010_bb0060","doi-asserted-by":"crossref","first-page":"P917","DOI":"10.1016\/j.jalz.2014.07.123","article-title":"A phase 2 trial of the efficacy and safety of the alpha7 agonist ABT-126 as an add-on treatment in mild-to-moderate Alzheimer's dementia","volume":"10","author":"Gault","year":"2014","journal-title":"Alzheimer's & Dementia: The Journal of the Alzheimer's Association"},{"key":"10.1016\/j.pbb.2017.05.010_bb0065","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0026-895X(25)09916-X","article-title":"Homomers of alpha 8 and alpha 7 subunits of nicotinic receptors exhibit similar channel but contrasting binding site properties","volume":"45","author":"Gerzanich","year":"1994","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.pbb.2017.05.010_bb0070","series-title":"Preclinical in Vitro and in Vivo Pharmacology of ABT-126: A Novel \u03b17 Nicotinic Acetylcholine Receptor Agonist for the Potential Treatment of Cognitive Deficits Associated With Schizophrenia and Alzheimer's Disease","author":"Gopalkrishnan","year":"2016"},{"key":"10.1016\/j.pbb.2017.05.010_bb0075","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.bcp.2009.07.005","article-title":"Selective alpha7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes","volume":"78","author":"Gurley","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.pbb.2017.05.010_bb0080","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/gbb.12113","article-title":"Genetic variation within the Chrna7 gene modulates nicotine reward-like phenotypes in mice","volume":"13","author":"Harenza","year":"2014","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.pbb.2017.05.010_bb0085","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/156802610790410983","article-title":"Neuronal nicotinic acetylcholine receptors-targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer's disease","volume":"10","author":"Haydar","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.pbb.2017.05.010_bb0090","article-title":"Nicotinic acetylcholine receptors: from structure to brain function, in Reviews of physiology, biochemistry and pharmacology pp 1-46","author":"Hogg","year":"2003","journal-title":"Spring"},{"key":"10.1016\/j.pbb.2017.05.010_bb0095","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00213-013-3027-7","article-title":"Assessment of the abuse liability of ABT-288, a novel histamine H(3) receptor antagonist","volume":"228","author":"Hudzik","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2017.05.010_bb0100","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0091-3057(01)00651-7","article-title":"Neurobiology of the nicotine withdrawal syndrome","volume":"70","author":"Kenny","year":"2001","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2017.05.010_bb0105","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/00008877-199911000-00014","article-title":"AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats","volume":"10","author":"Levin","year":"1999","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.pbb.2017.05.010_bb0110","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.bbr.2008.08.048","article-title":"Nicotinic \u03b17-or \u03b22-containing receptor knockout: effects on radial-arm maze learning and long-term nicotine consumption in mice","volume":"196","author":"Levin","year":"2009","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pbb.2017.05.010_bb0115","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/S0376-8716(03)00100-5","article-title":"Incorporating the assessment of abuse liability into the drug discovery and development process","volume":"70","author":"Mansbach","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pbb.2017.05.010_bb0120","series-title":"Nonclinical assessment of abuse potential for new pharmaceuticals","author":"Markgraf","year":"2015"},{"key":"10.1016\/j.pbb.2017.05.010_bb0125","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1146\/annurev.ph.57.030195.002513","article-title":"Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons","volume":"57","author":"McGehee","year":"1995","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.pbb.2017.05.010_bb0130","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00213-013-3207-5","article-title":"Discriminative-stimulus effects of NS9283, a nicotinic alpha4beta2* positive allosteric modulator, in nicotine-discriminating rats","volume":"231","author":"Mohler","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2017.05.010_bb0135","first-page":"989","article-title":"The functional observational battery in adult and developing rats","volume":"21","author":"Moser","year":"2000","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.pbb.2017.05.010_bb0140","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00702-006-0561-z","article-title":"Nicotinic receptor agonists as neuroprotective\/neurotrophic drugs. Progress in molecular mechanisms","volume":"114","author":"Mudo","year":"2007","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.pbb.2017.05.010_bb0145","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00213-009-1469-8","article-title":"The discriminative stimulus effects of N-methyl-d-aspartate glycine-site ligands in NMDA antagonist-trained rats","volume":"203","author":"Nicholson","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2017.05.010_bb0150","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.neubiorev.2010.10.012","article-title":"The predictive validity of the rat self-administration model for abuse liability","volume":"35","author":"O'Connor","year":"2011","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pbb.2017.05.010_bb0155","doi-asserted-by":"crossref","first-page":"P137","DOI":"10.1016\/j.jalz.2014.04.081","article-title":"Efficacy and safety of the ALPHA7 agonist ABT-126 as a monotherapy treatment in mild-to-moderate Alzheimer's dementia: results of a phase 2B trial","volume":"10","author":"Othman","year":"2014","journal-title":"Alzheimer's & Dementia: The Journal of the Alzheimer's Association"},{"key":"10.1016\/j.pbb.2017.05.010_bb0160","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3389\/fpubh.2013.00056","article-title":"Electronic cigarettes and vaping: a new challenge in clinical medicine and public health. A literature review","volume":"1","author":"Palazzolo","year":"2013","journal-title":"Front. Public Health"},{"key":"10.1016\/j.pbb.2017.05.010_bb0165","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1113\/jphysiol.1996.sp021203","article-title":"Neuronal nicotinic alpha 7 receptor expressed in Xenopus oocytes presents five putative binding sites for methyllycaconitine","volume":"491","author":"Palma","year":"1996","journal-title":"J. Physiol."},{"key":"10.1016\/j.pbb.2017.05.010_bb0170","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0301-0082(99)00045-3","article-title":"Neuronal nicotinic receptors in the human brain","volume":"61","author":"Paterson","year":"2000","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.pbb.2017.05.010_bb0175","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/34413","article-title":"Acetylcholine receptors containing the \u03b22 subunit are involved in the reinforcing properties of nicotine","volume":"391","author":"Picciotto","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.pbb.2017.05.010_bb0180","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/353846a0","article-title":"Mutations in the channel domain alter desensitization of a neuronal nicotinic receptor","volume":"353","author":"Revah","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.pbb.2017.05.010_bb0185","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s00213-004-1897-4","article-title":"Chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia","volume":"176","author":"Rueter","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2017.05.010_bb0190","doi-asserted-by":"crossref","first-page":"10035","DOI":"10.1523\/JNEUROSCI.1939-04.2004","article-title":"Decreased signs of nicotine withdrawal in mice null for the \u03b24 nicotinic acetylcholine receptor subunit","volume":"24","author":"Salas","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2017.05.010_bb0195","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0091-3057(94)90454-5","article-title":"Behavioral assessment of high-dose amphetamine withdrawal: importance of training and testing conditions","volume":"49","author":"Schindler","year":"1994","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2017.05.010_bb0200","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1248\/bpb.32.332","article-title":"Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models","volume":"32","author":"Shimohama","year":"2009","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.pbb.2017.05.010_bb0205","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00213-006-0596-8","article-title":"Ligands selective for \u03b14\u03b22 but not \u03b13\u03b24 or \u03b17 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat","volume":"190","author":"Smith","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2017.05.010_bb0210","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/nprot.2006.167","article-title":"Using drug-discrimination techniques to study the abuse-related effects of psychoactive drugs in rats","volume":"1","author":"Solinas","year":"2006","journal-title":"Nat. Protoc."},{"issue":"1","key":"10.1016\/j.pbb.2017.05.010_bb0215","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.neuropharm.2009.04.006","article-title":"Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of \u03b14\u03b22 nicotinic receptors in rats","volume":"57","author":"Spiller","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2017.05.010_bb0220","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.bcp.2009.07.005","article-title":"Selective \u03b17 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes","volume":"78","author":"Sydserff","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.pbb.2017.05.010_bb0225","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1099420","article-title":"Nicotine activation of \u03b14* receptors: sufficient for reward, tolerance, and sensitization","volume":"306","author":"Tapper","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.pbb.2017.05.010_bb0230","series-title":"WHO Report on the Global Tobacco Epidemic, 2008: The MPOWER Package","author":"WHO","year":"2008"},{"key":"10.1016\/j.pbb.2017.05.010_bb0235","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1523\/JNEUROSCI.23-08-03176.2003","article-title":"Differential desensitization and distribution of nicotinic acetylcholine receptor subtypes in midbrain dopamine areas","volume":"23","author":"Wooltorton","year":"2003","journal-title":"J. Neurosci."},{"issue":"Pt 3","key":"10.1016\/j.pbb.2017.05.010_bb0240","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1469-7793.1998.651bm.x","article-title":"Functional contribution of the alpha7 subunit to multiple subtypes of nicotinic receptors in embryonic chick sympathetic neurones","volume":"509","author":"Yu","year":"1998","journal-title":"J. Physiol."},{"key":"10.1016\/j.pbb.2017.05.010_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(97)01184-9","article-title":"Nicotine and heroin augment cocaine-induced dopamine overflow in nucleus accumbens","volume":"337","author":"Zernig","year":"1997","journal-title":"Eur. J. Pharmacol."}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305717301685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305717301685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T22:40:37Z","timestamp":1750286437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305717301685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":47,"alternative-id":["S0091305717301685"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2017.05.010","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical abuse liability assessment of ABT-126, an agonist at the \u03b17 nicotinic acetylcholine receptor (nAChR)","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2017.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}